|
AI-CHAT
CANCER
|
Mca02-022 | An integrative multimodal machine learning signature of primary resistance to immunotherapy in advanced non-small cell lung cancer: biomarker analysis from the PIONeeR study |
| Quote: | Conclusions: Multimodal machine learning integration of clinical, genomic, immune, and laboratory data enables improved prediction of ICI resistance in NSCLC beyond current biomarkers. This approach not only captures the multifaceted nature of tumourhost interactions but also highlights the underrecognized predictive value of accessible blood-based markers, offering a path toward individualized immunotherapy decision-making.
|
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.01.09.26343779v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.01.09.26343779v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Fabrice Barlesi Florence Monville Laurent Greillier Natalie Ngoi Joseph Ciccolini Florence Sabatier Stephane Garcia Jean-Philippe Dales Cyril Foa Laurent Arnaud Amlie Pouchin Frdric Vely Sivan Bokobza Anastasiia Bakhmach Andrea Vaglio Mlanie Karlsen Paul Dufoss Clarisse Audigier-Valette Jacques Letreut Lilian Laborde Pierre Milpied David Prol Mohamed Boussena Celestin Bigarre Mourad Hamimed Richard Malkoun Vanina Leca Marcellin Landri Maryannick Le Ray Marie Roumieux Julien Mazires Maurice Prol Jacques Fieschi-Meric Eric Vivier Sbastien Benzekry,
|
|
CANCER
|
Mga02-022 | Comparison of outcomes of second-line durvalumab plus tremelimumab and lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma |
| Quote: | Conclusions: After first-line Atezo/Beva, second-line Len achieved superior disease control and longer survival than Dur/Tre. However, grade #8805; 3 AEs were more frequent with Len than with Dur/Tre, and careful management of AEs is essential when choosing therapy for individual patients.
|
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.01.08.26343706v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.01.08.26343706v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Chinatsu Nishioka Yuki Tahata Kazuki Maesaka Machiko Kai Kumiko Shirai Kazuhiro Murai Yuki Makino Yoshinobu Saito Yasutoshi Nozaki Tasuku Nakabori Hisashi Ishida Takayuki Yakushijin Sadaharu Iio Nobuyuki Tatsumi Kazuho Imanaka Naruyasu Kakita Ryotaro Sakamori Atsushi Hosui Masanori Miyazaki Kengo Matsumoto Masanori Nakahara Yoshinori Doi Mitsuru Sakakibara Hayato Hikita Takahiro Kodama Tetsuo Takehara,
|
|
CANCER
|
Mim02-002 | Prognostic Value of IL21, CXCL9 and CD1A in Cervical Cancer |
| Quote: | Conclusion IL21, CXCL9 and CD1A are potential prognostic biomarkers and key immunomodulatory factors in cervical cancer. This study provides a new direction for immunotherapy and individualized precision treatment of cervical cancer.
|
| Abstract:
| https://www.medrxiv.org/content/10.64898/2026.01.08.26343702v1 |
| Full Text:
| https://www.medrxiv.org/content/10.64898/2026.01.08.26343702v1.full-text |
| Search Similar: |
Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho |
| Search Authors: |
Yanting Xu Yunyun Liu Zhaorong Guo,
|